Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.

Ellis JM, Altman MD, Bass A, Butcher JW, Byford AJ, Donofrio A, Galloway S, Haidle AM, Jewell J, Kelly N, Leccese EK, Lee S, Maddess M, Miller JR, Moy LY, Osimboni E, Otte RD, Reddy MV, Spencer K, Sun B, Vincent SH, Ward GJ, Woo GH, Yang C, Houshyar H, Northrup AB.

J Med Chem. 2015 Feb 26;58(4):1929-39. doi: 10.1021/jm5018169. Epub 2015 Feb 16.

PMID:
25625541
2.

Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.

Xiong Y, Guo J, Candelore MR, Liang R, Miller C, Dallas-Yang Q, Jiang G, McCann PE, Qureshi SA, Tong X, Xu SS, Shang J, Vincent SH, Tota LM, Wright MJ, Yang X, Zhang BB, Tata JR, Parmee ER.

J Med Chem. 2012 Jul 12;55(13):6137-48. doi: 10.1021/jm300579z. Epub 2012 Jun 28.

PMID:
22708876
3.

Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.

Beconi MG, Reed JR, Teffera Y, Xia YQ, Kochansky CJ, Liu DQ, Xu S, Elmore CS, Ciccotto S, Hora DF, Stearns RA, Vincent SH.

Drug Metab Dispos. 2007 Apr;35(4):525-32. Epub 2007 Jan 12.

4.

Characterization of two cyclic metabolites of sitagliptin.

Liu DQ, Arison BH, Stearns RA, Kim D, Vincent SH.

Drug Metab Dispos. 2007 Apr;35(4):521-4. Epub 2007 Jan 12.

5.

Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.

Vincent SH, Reed JR, Bergman AJ, Elmore CS, Zhu B, Xu S, Ebel D, Larson P, Zeng W, Chen L, Dilzer S, Lasseter K, Gottesdiener K, Wagner JA, Herman GA.

Drug Metab Dispos. 2007 Apr;35(4):533-8. Epub 2007 Jan 12.

6.

Absorption, metabolism, and excretion of [14C]MK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in humans.

Kochansky CJ, Rippley RK, Yan KX, Song H, Wallace MA, Dean D, Jones AN, Lasseter K, Schwartz J, Vincent SH, Franklin RB, Wagner J.

Drug Metab Dispos. 2006 Sep;34(9):1457-61. Epub 2006 Jun 13.

7.

Species differences in metabolism and pharmacokinetics of a sphingosine-1-phosphate receptor agonist in rats and dogs: formation of a unique glutathione adduct in the rat.

Anari MR, Creighton MD, Ngui JS, Tschirret-Guth RA, Teffera Y, Doss GA, Tang W, Yu NX, Ciccotto SL, Hobra DF Jr, Coleman JB, Vincent SH, Evans DC.

Drug Metab Dispos. 2006 Aug;34(8):1367-75. Epub 2006 May 12.

8.

Species differences in the elimination of a peroxisome proliferator-activated receptor agonist highlighted by oxidative metabolism of its acyl glucuronide.

Kochansky CJ, Xia YQ, Wang S, Cato B, Creighton M, Vincent SH, Franklin RB, Reed JR.

Drug Metab Dispos. 2005 Dec;33(12):1894-904. Epub 2005 Sep 23.

9.

Mechanistic studies on the metabolic scission of thiazolidinedione derivatives to acyclic thiols.

Reddy VB, Karanam BV, Gruber WL, Wallace MA, Vincent SH, Franklin RB, Baillie TA.

Chem Res Toxicol. 2005 May;18(5):880-8.

PMID:
15892582
10.

Differences in the metabolism and pharmacokinetics of two structurally similar PPAR agonists in dogs: involvement of taurine conjugation.

Kim MS, Shen Z, Kochansky C, Lynn K, Wang S, Wang Z, Hora D, Brunner J, Franklin RB, Vincent SH.

Xenobiotica. 2004 Jul;34(7):665-74.

PMID:
15672754
12.
14.

Simultaneous determination of MK-0767 and seven metabolites in rat urine using liquid chromatography/tandem mass spectrometry.

Shen Z, Kochansky C, Bakhtiar R, Franklin RB, Vincent SH.

Rapid Commun Mass Spectrom. 2004;18(18):2113-20.

PMID:
15317046
16.

Metabolism and disposition of gemfibrozil in Wistar and multidrug resistance-associated protein 2-deficient TR- rats.

Kim MS, Liu DQ, Strauss JR, Capodanno I, Yao Z, Fenyk-Melody JE, Franklin RB, Vincent SH.

Xenobiotica. 2003 Oct;33(10):1027-42.

PMID:
14555339
17.

Induction of hepatic phase II drug-metabolizing enzymes by 1,7-phenanthroline in rats is accompanied by induction of MRP3.

Wang S, Hartley DP, Ciccotto SL, Vincent SH, Franklin RB, Kim MS.

Drug Metab Dispos. 2003 Jun;31(6):773-5.

18.

Identification of novel metabolites of pioglitazone in rat and dog.

Shen Z, Reed JR, Creighton M, Liu DQ, Tang YS, Hora DF, Feeney W, Szewczyk J, Bakhtiar R, Franklin RB, Vincent SH.

Xenobiotica. 2003 May;33(5):499-509.

PMID:
12746106
19.

Modification of the pyridine moiety of non-peptidyl indole GnRH receptor antagonists.

Simeone JP, Bugianesi RL, Ponpipom MM, Yang YT, Lo JL, Yudkovitz JB, Cui J, Mount GR, Ren RN, Creighton M, Mao AH, Vincent SH, Cheng K, Goulet MT.

Bioorg Med Chem Lett. 2002 Nov 18;12(22):3329-32.

PMID:
12392744
20.

2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.

Young JR, Huang SX, Walsh TF, Wyvratt MJ, Yang YT, Yudkovitz JB, Cui J, Mount GR, Ren RN, Wu TJ, Shen X, Lyons KA, Mao AH, Carlin JR, Karanam BV, Vincent SH, Cheng K, Goulet MT.

Bioorg Med Chem Lett. 2002 Mar 11;12(5):827-32.

PMID:
11859012
22.

Orally bioavailable, indole-based nonpeptide GnRH receptor antagonists with high potency and functional activity.

Ashton WT, Sisco RM, Kieczykowski GR, Yang YT, Yudkovitz JB, Cui J, Mount GR, Ren RN, Wu TJ, Shen X, Lyons KA, Mao AH, Carlin JR, Karanam BV, Vincent SH, Cheng K, Goulet MT.

Bioorg Med Chem Lett. 2001 Oct 8;11(19):2597-602.

PMID:
11551758
24.

Disposition of L-732,531, a potent immunosuppressant, in rats and baboons.

Karanam BV, Miller RR, Colletti A, Montgomery T, Carey KD, Hawkins T, Tang YS, Lavin M, Stearns RA, Chiu SH, Vincent SH.

Drug Metab Dispos. 1998 Oct;26(10):949-57.

25.

Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.

Thompson KL, Vincent SH, Miller RR, Colletti AE, Alvaro RF, Wallace MA, Feeney WP, Chiu SH.

Drug Metab Dispos. 1997 Oct;25(10):1113-8.

26.
27.

Orally active inhibitors of human leukocyte elastase. II. Disposition of L-694,458 in rats and rhesus monkeys.

Vincent SH, Painter SK, Luffer-Atlas D, Karanam BV, McGowan E, Cioffe C, Doss G, Chiu SH.

Drug Metab Dispos. 1997 Aug;25(8):932-9.

28.

Orally active inhibitors of human leukocyte elastase. I. Disposition of L-683,845 in rats and rhesus monkeys.

Vincent SH, Painter SK, Krieter PA, Colletti AE, Lyszack E, Rosegay A, Dean D, Luffer-Atlas D, Miller RR, Cioffe C, Chiu SH.

Drug Metab Dispos. 1996 Dec;24(12):1369-77.

PMID:
8971144
29.

The role of drug metabolism in drug discovery: a case study in the selection of an oxytocin receptor antagonist for development.

Chiu SH, Thompson KA, Vincent SH, Alvaro RF, Huskey SW, Stearns RA, Pettibone DJ.

Toxicol Pathol. 1995 Mar-Apr;23(2):124-30. Review.

PMID:
7569665
30.

FK 506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isozymes other than CYP3A4.

Karanam BV, Vincent SH, Newton DJ, Wang RW, Chiu SH.

Drug Metab Dispos. 1994 Sep-Oct;22(5):811-4. No abstract available. Erratum in: Drug Metab Dispos 1994 Nov-Dec;22(6):979.

PMID:
7530623
32.

Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase.

Vincent SH, Wang RW, Karanam BV, Klimko M, Alvaro R, Chiu SH.

Biochem Pharmacol. 1991 May 1;41(9):1325-30.

PMID:
1708254
34.

Protein-mediated efflux of heme from isolated rat liver mitochondria.

Liem HH, Grasso JA, Vincent SH, Muller-Eberhard U.

Biochem Biophys Res Commun. 1990 Mar 16;167(2):528-34.

PMID:
2322241
36.

Interaction of hemopexin, albumin and liver fatty acid-binding protein with protoporphyrin.

Knobler E, Poh-Fitzpatrick MB, Kravetz D, Vincent WR, Muller-Eberhard U, Vincent SH.

Hepatology. 1989 Dec;10(6):995-7.

PMID:
2583692
37.
38.

Oxidative effects of heme and porphyrins on proteins and lipids.

Vincent SH.

Semin Hematol. 1989 Apr;26(2):105-13. Review.

PMID:
2658086
39.

Decreased cytosolic levels of the heme binding Z protein in rat hepatocyte nodules and hepatocellular carcinomas.

Roomi MW, Vincent SH, Farber E, Muller-Eberhard U.

Cancer Lett. 1988 Dec 1;43(1-2):55-8.

PMID:
3203330
40.

The influence of heme-binding proteins in heme-catalyzed oxidations.

Vincent SH, Grady RW, Shaklai N, Snider JM, Muller-Eberhard U.

Arch Biochem Biophys. 1988 Sep;265(2):539-50.

PMID:
3421724
41.

Diagnostic labels, treatment and outcome in acute sore throat.

Pitts J, Vincent SH.

Practitioner. 1988 Mar 22;232(1445):343-6. No abstract available.

PMID:
3217342
43.

Porphyrin-induced photodynamic cross-linking of hepatic heme-binding proteins.

Vincent SH, Holeman B, Cully BC, Muller-Eberhard U.

Life Sci. 1986 Jan 27;38(4):365-72.

PMID:
2418327
44.

Cardiovascular responses in healthy subjects to a novel oral dopamine agonist, fenoldopam.

Cregeen RJ, Rudge PJ, Mills JG, Vincent SH, Burland WL.

J Hypertens Suppl. 1985 Dec;3(3):S173-5.

PMID:
2908814
45.

A protein of the Z class of liver cytosolic proteins in the rat that preferentially binds heme.

Vincent SH, Muller-Eberhard U.

J Biol Chem. 1985 Nov 25;260(27):14521-8.

46.

Purification and characterization of protein Z from rabbit liver cytosol.

Vincent SH, Holeman B, Muller-Eberhard U.

Biochem Biophys Res Commun. 1985 Oct 30;132(2):575-81.

PMID:
4062940
47.

Concepts of heme distribution within hepatocytes.

Muller-Eberhard U, Vincent SH.

Biochem Pharmacol. 1985 Mar 15;34(6):719-25. Review. No abstract available.

PMID:
3884016
48.

Proton transfer in the catalytic mechanism of carbonic anhydrase.

Silverman DN, Vincent SH.

CRC Crit Rev Biochem. 1983;14(3):207-55. Review. No abstract available.

PMID:
6313293
49.

Carbonic anhydrase activity in mitochondria from rat liver.

Vincent SH, Silverman DN.

J Biol Chem. 1982 Jun 25;257(12):6850-5.

50.

Tissue distribution studies of [18F]haloperidol, [18F]-beta-(4-fluorobenzoyl)propionic acid, and [82Br]bromperidol by external scintigraphy.

Digenis GA, Vincent SH, Kook CS, Reiman RE, Russ GA, Tilbury RS.

J Pharm Sci. 1981 Sep;70(9):985-9.

PMID:
6101168

Supplemental Content

Loading ...
Support Center